Emergent BioSolutions Inc. - COMMON STOCK (EBS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
EBS on NYSE
Shares outstanding
52,870,098
Price per share
$12.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
32,025,507
Total reported value
$395,850,544
% of total 13F portfolios
0%
Share change
+1,296,721
Value change
+$19,058,651
Number of holders
129
Price from insider filings
$12.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Emergent BioSolutions Inc. - COMMON STOCK (EBS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.3% $25,376,673 3,977,535 BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 6.8% $43,927,428 3,553,999 The Vanguard Group 31 Dec 2025
STATE STREET CORP 5.1% $33,408,086 2,696,375 STATE STREET CORPORATION 31 Dec 2025

As of 31 Dec 2025, 129 institutional investors reported holding 32,025,507 shares of Emergent BioSolutions Inc. - COMMON STOCK (EBS). This represents 61% of the company’s total 52,870,098 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Emergent BioSolutions Inc. - COMMON STOCK (EBS) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8% 4,254,397 -0.2% 0% $52,584,347
VANGUARD GROUP INC 6.7% 3,553,999 +0.38% 0% $43,927,428
STATE STREET CORP 5.1% 2,696,375 +10% 0% $33,327,195
AMERICAN CENTURY COMPANIES INC 4.6% 2,439,439 +2.4% 0.02% $30,151,466
DIMENSIONAL FUND ADVISORS LP 4.3% 2,252,605 +5.2% 0.01% $27,840,949
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3.1% 1,618,903 +17% 0% $20,009,641
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,250,010 -2.2% 0% $15,453,820
MORGAN STANLEY 2.2% 1,157,696 +119% 0% $14,309,141
ACADIAN ASSET MANAGEMENT LLC 2.1% 1,110,682 -5.7% 0.02% $13,723,000
LSV ASSET MANAGEMENT 1.7% 901,000 +4.2% 0.02% $11,136,000
Connor, Clark & Lunn Investment Management Ltd. 1.5% 777,999 -31% 0.03% $9,616,068
Prescott Group Capital Management, L.L.C. 1.5% 772,771 0% 0.89% $9,551,450
MARSHALL WACE, LLP 1.4% 743,455 -19% 0.01% $9,189,104
GOLDMAN SACHS GROUP INC 1.4% 740,100 +19% 0% $9,147,636
RENAISSANCE TECHNOLOGIES LLC 1.1% 577,147 +11% 0.01% $7,133,537
NEW YORK STATE COMMON RETIREMENT FUND 0.99% 522,004 0% 0.01% $6,451,969
FEDERATED HERMES, INC. 0.82% 434,774 +8.4% 0.01% $5,373,807
JANE STREET GROUP, LLC 0.75% 395,457 0.01% $4,887,849
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.71% 373,902 +153% 0.03% $4,621,429
UBS Group AG 0.66% 347,805 -21% 0% $4,298,870
HRT FINANCIAL LP 0.59% 311,784 0.01% $3,853,000
Values First Advisors, Inc. 0.58% 305,046 -17% 2% $3,770,373
Allianz Asset Management GmbH 0.55% 290,701 +3.9% 0% $3,593,064
Bank of New York Mellon Corp 0.46% 244,512 +59% 0% $3,022,163
GLOBEFLEX CAPITAL L P 0.46% 241,298 0% 0.46% $2,982,443

Institutional Holders of Emergent BioSolutions Inc. - COMMON STOCK (EBS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 32,025,507 $395,850,544 +$19,058,651 $12.36 129
2025 Q3 41,696,734 $352,475,753 +$19,667,092 $8.82 167
2025 Q2 36,048,259 $229,963,501 +$8,627,423 $6.38 159
2025 Q1 36,190,861 $175,869,555 +$2,175,881 $4.86 158
2024 Q4 34,731,466 $332,026,231 +$28,116,282 $9.56 155
2024 Q3 31,685,912 $264,526,545 +$30,958,222 $8.35 137
2024 Q2 30,424,097 $207,508,937 -$26,587,800 $6.82 137
2024 Q1 35,915,952 $90,810,710 -$12,044,764 $2.53 115
2023 Q4 40,884,124 $98,125,874 -$3,033,553 $2.40 129
2023 Q3 41,326,491 $140,783,681 -$26,266,322 $3.40 159
2023 Q2 45,670,504 $335,708,725 +$1,389,547 $7.35 177
2023 Q1 44,931,082 $465,319,997 -$16,940,760 $10.36 187
2022 Q4 46,237,482 $546,050,427 +$42,157,405 $11.81 193
2022 Q3 40,630,823 $852,783,613 -$48,608,549 $20.99 192
2022 Q2 41,191,389 $1,278,322,431 -$19,204,360 $31.04 217
2022 Q1 41,761,849 $1,714,987,525 -$22,633,768 $41.06 234
2021 Q4 42,514,559 $1,849,372,320 -$107,864,716 $43.47 243
2021 Q3 44,511,870 $2,228,860,734 -$18,391,350 $50.07 270
2021 Q2 44,739,294 $2,817,444,749 -$43,662,628 $62.99 286
2021 Q1 44,459,246 $4,122,801,151 +$64,719,540 $92.91 334
2020 Q4 44,267,661 $3,967,537,088 +$93,758,805 $89.60 350
2020 Q3 42,899,052 $4,434,039,819 -$189,544,769 $103.33 355
2020 Q2 53,497,347 $4,185,752,138 +$625,343,109 $79.08 295
2020 Q1 44,884,797 $2,596,632,152 +$7,885,727 $57.86 257
2019 Q4 44,601,650 $2,406,425,656 -$6,082,616 $53.95 232
2019 Q3 44,748,551 $2,338,743,757 -$21,935,074 $52.28 241
2019 Q2 45,520,096 $2,198,644,219 +$64,447,863 $48.31 229
2019 Q1 44,845,040 $2,265,671,390 +$80,862,293 $50.52 265
2018 Q4 43,083,866 $2,553,149,934 +$34,101,099 $59.28 293
2018 Q3 42,429,433 $2,792,382,193 +$14,853,355 $65.83 269
2018 Q2 42,572,970 $2,149,894,709 +$23,723,394 $50.49 257
2018 Q1 42,080,510 $2,209,520,816 +$57,029,193 $52.65 270
2017 Q4 40,397,491 $1,878,364,516 +$151,859,986 $46.47 234
2017 Q3 37,088,695 $1,500,432,961 +$64,446,291 $40.45 193
2017 Q2 35,621,344 $1,199,488,524 +$6,414,221 $33.91 179
2017 Q1 35,579,837 $1,033,330,673 +$100,066,486 $29.04 173
2016 Q4 35,742,013 $1,173,028,889 -$3,279,137 $32.84 204
2016 Q3 35,869,477 $1,129,692,915 -$1,485,647 $31.53 197
2016 Q2 36,161,934 $1,016,934,072 +$82,512,424 $28.12 215
2016 Q1 33,583,921 $1,221,359,935 +$19,065,121 $36.35 211
2015 Q4 32,446,135 $1,298,005,471 +$24,674,059 $40.01 202
2015 Q3 32,168,577 $916,516,058 +$35,690,135 $28.49 191
2015 Q2 31,043,093 $1,022,845,909 +$25,560,178 $32.95 181
2015 Q1 30,395,864 $874,182,011 +$38,137,574 $28.76 169
2014 Q4 29,096,913 $792,405,069 -$719,286 $27.23 163
2014 Q3 28,825,281 $614,994,160 -$30,742 $21.31 158
2014 Q2 28,744,311 $645,587,994 -$436,657 $22.46 157
2014 Q1 28,580,751 $722,288,209 +$89,513,027 $25.27 163